
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is well-positioned to enter the market of cancer treatment with their innovative and promising CAR-T therapy, which has shown positive initial efficacy and lower toxicity. The company also has potential for growth through their development of therapies for autoimmune diseases and their exploration of new treatments for lupus nephritis and multiple sclerosis, supported by promising results and potential market growth. Their focus on developing therapies for previously underserved patient populations, such as older and frailer patients, also presents an opportunity for Autolus to gain a significant market share in the industry.
Bears say
Autolus Therapeutics is currently facing a negative outlook due to its high cost of goods sold, significant operating losses, and lack of near-term revenue drivers. Additionally, the company's financials are not strong enough to support its high valuation, making it a risky investment.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares